#United States #New York #Class Action #Investor Rights #Quantum Biopharma

Investor Alert: Class Action Against Quantum Biopharma Ltd.

In a significant development for shareholders of Quantum Biopharma Ltd. (NASDAQ: QNTM), Bronstein, Gewirtz & Grossman, LLC, a highly regarded firm specializing in investor rights, has initiated a class action lawsuit against the Canadian Imperial Bank of Commerce (CIBC) and the Royal Bank of Canada (RBC), along with their affiliated broker-dealers. This legal action accuses the defendants of engaging in fraudulent trading practices that purportedly manipulated the market, thereby harming numerous investors.

Details of the Class Action

The complaint asserts that during the Class Period, which spans from January 6, 2021, to October 15, 2025, the defendants executed a series of manipulative trades designed to artificially depress the stock price of Quantum Biopharma. Specifically, it is alleged that the defendants entered thousands of deceptive sell orders, falsely presenting a narrative that Quantum's stock was in decline. This tactic not only misled existing shareholders but also induced them to sell their stocks at significantly reduced prices.

This class action is aimed at recovering damages for all parties who sold Quantum securities within the specified timeframe. The law firm encourages affected investors to become involved with the case, which can be accessed through bgandg.com/QNTM.

Allegations Against the Defendants

1. Spoofing Trades: The lawsuit alleges that the defendants repeatedly engaged in placing fake sell orders, creating a perception of a plummeting stock price.
2. Misleading Information: They allegedly failed to disclose critical information related to their trading practices, subsequently misleading investors.
3. Induction to Sell: This fraudulent behavior led to investors, including the named plaintiff, selling shares at prices driven lower than their actual worth.
4. Profiting from the Scheme: Post manipulation, the defendants are said to have purchased shares at these artificially lowered prices, positioning themselves for financial gain at the expense of other investors.

What’s Next for Investors?

Investors who believe they have suffered losses related to Quantum Biopharma are encouraged to take action promptly. The law firm is available for those who would like to review the complaint or have any questions regarding their potential involvement in the class action. Interested parties have until February 23, 2026, to request to be appointed as lead plaintiff in the case, although participation in any recovery does not require this designation.

No Upfront Costs for Participants

Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning that they will only receive compensation for their legal expenses if the case is successful. This allows pursuing justice without financial barriers, presenting an opportunity for all affected investors to reclaim part of their losses.

Why Choose Bronstein, Gewirtz & Grossman, LLC?

The firm is recognized nationally for its dedication to representing investors in securities fraud cases and has successfully recovered hundreds of millions for clients nationwide. According to Peretz Bronstein, the firm's Founding Partner, “Our focus is on restoring investor capital and maintaining accountability within corporations, which upholds the integrity of the market.”

Stay Updated

For continuous updates regarding the class action and other related information, interested parties are encouraged to follow Bronstein, Gewirtz & Grossman on LinkedIn, X, Facebook, or Instagram. For further inquiries, reach out to Peretz Bronstein, Esq. or Nathan Miller at the firm, contactable at (917) 590-0911.

Navigating legal processes can be daunting, but with the right representation, investors have a fighting chance to reclaim their losses and promote transparency in market practices.